Low-Dose Estradiol and the Serotonin-Norepinephrine Reuptake Inhibitor Venlafaxine for Vasomotor Symptoms
Author(s) -
Hadine Joffe,
Katherine A. Guthrie,
Andrea Z. LaCroix,
Susan D. Reed,
Kristine E. Ensrud,
JoAnn E. Manson,
Katherine M. Newton,
Ellen W. Freeman,
Garnet L. Anderson,
Joseph C. Larson,
Julie R. Hunt,
Jan L. Shifren,
Kathryn M. Rexrode,
Bette J. Caan,
Barbara Sternfeld,
Janet S. Carpenter,
Lee S. Cohen
Publication year - 2014
Publication title -
jama internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.14
H-Index - 342
eISSN - 2168-6114
pISSN - 2168-6106
DOI - 10.1001/jamainternmed.2014.1891
Subject(s) - venlafaxine , venlafaxine hydrochloride , medicine , tolerability , vasomotor , placebo , reuptake inhibitor , serotonin reuptake inhibitor , antidepressant , estrogen , menopause , sertraline , anesthesia , endocrinology , adverse effect , alternative medicine , pathology , hippocampus
Estrogen therapy is the gold standard treatment for hot flashes and night sweats, but some women are unable or unwilling to use it because of associated risks. The serotonin-norepinephrine reuptake inhibitor venlafaxine hydrochloride is used widely as a nonhormonal treatment. While the clinical impression is that serotonin-norepinephrine reuptake inhibitors are less effective than estrogen, these medications have not been simultaneously evaluated in one clinical trial to date.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom